Huang Yongkang, Liu De-E, An Jinxia, Liu Bingqing, Sun Liya, Fu Hao, Yan Shuzhen, Sun Wenfang, Gao Hui
Tianjin Key Laboratory of Drug Targeting and Bioimaging, Tianjin Enterprise Key Laboratory for Application Research of Hyaluronic Acid, School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin 300384, P. R. China.
Department of Chemistry and Biochemistry, North Dakota State University, Fargo, North Dakota 58108-6050, United States.
ACS Appl Bio Mater. 2020 Dec 21;3(12):9135-9144. doi: 10.1021/acsabm.0c01419. Epub 2020 Dec 7.
Developing multifunctional nanoplatforms that combine controlled drug release, therapy, and real-time monitoring of intracellular distribution of therapeutic agents can provide a solution for practical precision cancer therapy. Herein, a daylight activatable and red to near-infrared (NIR) dual-imaging guided multifunctional anticancer nanoplatform based on diselenium-conjugated and aggregation-induced emission fluorogen (AIEgen)-cross-linked oligoethylenimine polymer loaded with cisplatin (Pt) and biscyclometalated iridium(III) (Ir(III)) complex (Pt&Ir@P NPs) is reported. Upon short-time daylight irradiation, the nanoplatform generates reactive oxygen species (ROS), which help them to escape from endo/lysosomes via enhanced lysosomal membrane permeability. Meanwhile, the chemotherapeutic drug cisplatin and the photosensitizer (PS) Ir(III) complex are released via breaking the ROS-labile diselenium bond. The released PS, together with AIEgen, respond to the continuous long-time daylight irradiation and produce more ROS, inducing photodynamic therapy (PDT) and damaging the nucleus. Along with PDT, selenium liberates cisplatin and exerts chemotherapy in the presence of endogenous spermine. In addition, the red/NIR emitting Ir(III) complex and the engineered AIEgen act as dual-imaging agents for real-time monitoring the distribution of PS and polymer. This daylight responsive multifunctional nanoplatform for efficient anticancer therapy and imaging could provide an intriguing strategy for developing theranostic antitumor platforms.
开发结合可控药物释放、治疗以及对治疗剂细胞内分布进行实时监测的多功能纳米平台,可为实际的精准癌症治疗提供解决方案。在此,我们报道了一种基于负载顺铂(Pt)和双环金属化铱(III)(Ir(III))配合物(Pt&Ir@P NPs)的二硒共轭和聚集诱导发光荧光团(AIEgen)交联的低聚乙二胺聚合物的日光可激活且从红色到近红外(NIR)双成像引导的多功能抗癌纳米平台。在短时间日光照射下,该纳米平台产生活性氧(ROS),通过增强溶酶体膜通透性帮助它们从内体/溶酶体中逃逸。同时,化疗药物顺铂和光敏剂(PS)Ir(III)配合物通过断裂对ROS敏感的二硒键释放出来。释放出的PS与AIEgen一起,对持续的长时间日光照射做出响应并产生更多ROS,诱导光动力疗法(PDT)并损伤细胞核。伴随着PDT,硒释放出顺铂并在内源性精胺存在的情况下发挥化疗作用。此外,发射红色/NIR光的Ir(III)配合物和经过工程设计的AIEgen作为双成像剂,用于实时监测PS和聚合物的分布。这种对日光响应的用于高效抗癌治疗和成像的多功能纳米平台,可为开发治疗诊断一体化抗肿瘤平台提供一种引人关注的策略。